Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: GlobalData
$125.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sucampo Pharmaceuticals Inc's AMITIZA (Lubiprostone) receives NICE recommendation


Tuesday, 17 Jun 2014 08:06pm EDT 

Sucampo Pharmaceuticals Inc:Says that United Kingdom's National Institute of Health and Care Excellence (NICE) has released final appraisal determination with guidance for recommendation of use of AMITIZA (lubiprostone) in treatment of chronic idiopathic constipation and associated symptoms in adults who have failed laxatives. 

Company Quote

13.57
0.13 +0.97%
19 Dec 2014